PeptiDream's first-quarter results met expectations; pipeline progress and external licensing remain the key catalysts

Overview

This report is Goldman Sachs' review of PeptiDream (4587.T)'s first-quarter results. The company's 1Q FY12/26 operating loss was ￥1.1 bn, essentially in line with Goldman Sachs' expected loss of ￥1.3 bn; sales of ￥4.8 bn also came close to the estimated ￥4.5 bn. The report concludes that near-term earnings upside is limited, but the development pipeline being advanced through the proprietary drug discovery platform PDPS is progressing steadily. In particular, partner Asahi Kasei Therapeutics' initiation of Phase I clinical testing for the selective TNF receptor 1 inhibitor AK1940 provides support for future catalysts.

Core views

Goldman Sachs maintained its Buy rating on PeptiDream, with the core view that the company's long-term earnings outlook may improve from two directions: first, the initiation of clinical trials for in-house and partnered products, with the company expecting 6 to 12 projects to enter the clinic in 2026; second, external licensing of in-house products, including projects such as myostatin inhibitors and IL-17 inhibitors. Goldman Sachs also emphasized that PeptiDream, as a biotechnology company with the proprietary peptide discovery platform system PDPS, stands to benefit from the prospect that special peptide drugs combine the advantages of small-molecule and biologic drugs, and that the expansion of PDPS licensing business partners, partner pipeline progress, and the synergies from the radiopharmaceutical business acquired in 2022 should all support long-term growth.

Analysis framework

The report uses an earnings comparison, pipeline catalyst tracking, and DCF valuation framework. On the earnings side, it compares 1Q sales and operating loss with Goldman Sachs estimates; on the pipeline side, it tracks clinical or filing milestones for projects such as AK1940, CA9, CLDN18.2, 64Cu-PSMA I&T, and 64Cu-ATSM; on the valuation side, the target price is based on a 15-year DCF model, assuming an 8% WACC and a 0% terminal growth rate.

Methodology notes

• Valuation method15-year DCF model

  Discounted cash flow valuation

  Goldman Sachs' 12-month target price of ￥2,750 is based on a 15-year DCF model, with key assumptions including an 8% WACC and a 0% terminal growth rate.

• Investment ratingGoldman Sachs Buy rating

  Total return potential versus the coverage universe

  The report maintains a Buy rating, reflecting Goldman Sachs' view that PeptiDream offers attractive total return potential relative to the coverage universe.

• Factor analysisGS Factor Profile

  Growth, financial return, valuation multiples, and composite percentile comparisons

  The report discloses that Goldman Sachs' factor framework compares a stock's growth, financial return, valuation multiples, and composite metrics versus the market and industry peers.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• PeptiDream (4587.T)

  Research coverage target; a Japanese-listed biotechnology company

  Strengths

  Owns the proprietary peptide discovery platform PDPS; special peptide drugs may offer differentiated advantages; partner expansion and pipeline progress provide long-term growth visibility; the radiopharmaceutical business may create synergies.

  Weaknesses

  The company is still reporting operating losses this quarter; valuation depends heavily on future pipeline progress, licensing timing, and long-term earnings realization.

  Comparison

  Goldman Sachs believes the stock looks undervalued relative to its long-term earnings growth visibility and pipeline outlook.

  Risks

  Partner project suspensions or delays, changes in partner development strategy, the emergence of drug discovery technologies that can replace the company's core technology, and financing risk from development delays or more aggressive business investment.

• PDPS technology licensing business

  One of the core platform and long-term profit growth drivers

  Strengths

  Expands platform value through partner growth and licensing business, and can advance partner pipelines.

  Weaknesses

  Value realization depends on partner development capability, clinical data, and licensing commercial terms.

  Comparison

  Compared with a single-drug asset, a platform business can offer more potential projects and collaboration opportunities.

  Risks

  Partner project discontinuation, changes in development strategy, or the emergence of external substitute technologies.

• Radiopharmaceutical business

  A potential synergistic business formed after the 2022 acquisition

  Strengths

  Projects such as CA9, CLDN18.2, 64Cu-PSMA I&T, and 64Cu-ATSM provide catalysts for clinical and filing milestones.

  Weaknesses

  Still requires clinical progress, regulatory filings, and commercialization validation.

  Comparison

  As a business expansion beyond the PDPS platform, it can broaden the company's pipeline.

  Risks

  Clinical trial, regulatory approval, or development progress coming in below expectations.

Key data

• 1Q FY12/26 sales￥4.8 bnGoldman Sachs estimated ￥4.5 bn, so the actual result was broadly in line with expectations.
• 1Q FY12/26 operating loss￥1.1 bnGoldman Sachs estimated a ￥1.3 bn loss; the actual result was slightly better but still broadly in line with expectations.
• 12-month target price￥2,750The target price is unchanged and is based on a 15-year DCF model.
• Key DCF assumptionsWACC 8%; terminal growth rate 0%Used to support the ￥2,750 target price.
• Projects expected to enter the clinic in 20266-12 projectsIncluding both in-house and partnered products.
• Japan filing plan2027The company expects to file for its 64Cu-PSMA I&T and 64Cu-ATSM radiopharmaceutical projects in Japan.

Impact & implications

The investment implication of this report is that the key issue is not the near-term quarterly results, but whether pipeline milestones can continue to be delivered and lead the market to revise long-term earnings expectations upward. If multiple projects enter the clinic in 2026, partners continue advancing PDPS-related products, and external licensing of in-house pipelines materializes, PeptiDream's platform value and future earnings visibility could improve further. Conversely, clinical development delays, changes in partner strategy, or the emergence of alternative drug discovery technologies would weaken valuation support.

Risks

• Partners suspend or delay development projects.
• Partners change development strategies, affecting progress on PeptiDream-related projects.
• A drug discovery technology emerges that can replace the company's proprietary technology.
• Development delays or more aggressive business investment may create financing risk.
• Clinical data, filing progress, or external licensing for the in-house or partnered pipeline falls short of expectations.

What to watch

• Whether 6 to 12 in-house and partnered projects enter clinical trials in 2026 as expected.
• Progress in Asahi Kasei Therapeutics' Phase I AK1940 clinical trial.
• Whether the in-house radiopharmaceutical projects CA9 and CLDN18.2 can enter the clinic within the year.
• Progress on the 2027 Japan filing plan for 64Cu-PSMA I&T and 64Cu-ATSM.
• External licensing progress for in-house products such as myostatin inhibitors and IL-17 inhibitors.
• Expansion of PDPS technology licensing partners and the build-out of clinical evidence for special peptide drugs.